nach oben

Erschienen in:

01.11.2007 | Pediatric Original

Enoxaparin therapy for arterial thrombosis in infants with congenital heart disease

verfasst von: Joe Bontadelli, Alexander Moeller, Markus Schmugge, Thomas Schraner, Oliver Kretschmar, Urs Bauersfeld, Vera Bernet-Buettiker, Manuela Albisetti

Erschienen in: Intensive Care Medicine | Ausgabe 11/2007

Einloggen, um Zugang zu erhalten

Abstract

Objective

To investigate efficacy and safety of enoxaparin for catheter-related arterial thrombosis in infants with congenital heart disease.

Design

Prospective observational study.

Setting

Pediatric Intensive Care and Cardiology Unit at the University Children's Hospital of Zurich.

Patients

A cohort of 32 infants aged 0–12 months treated with enoxaparin for catheter-related arterial thrombosis from 2002 to 2005.

Measurements

Dose requirements of enoxaparin, resolution of thrombosis by Doppler ultrasound, and bleeding complications.

Results

Catheter-related arterial thrombosis was located in the iliac/femoral arteries in 31 (97%) infants and aorta in 1 infant, and was related to indwelling catheters and cardiac catheterization in 17 (53%) and 15 (47%) cases, respectively. Newborns required increased doses of enoxaparin to achieve therapeutic anti-FXa levels (mean 1.62 mg/kg per dose) compared with infants aged 2–12 months (mean 1.12 mg/kg per dose; p = 0.0002). Complete resolution of arterial thrombosis occurred in 29 (91%) infants at a mean of 23 days after initiation of enoxaparin therapy. Partial or no resolution was observed in 1 (3%) and 2 (6%) infants, respectively, at a mean follow-up time of 4.3 months. Bleeding complications occurred in 1 (3%) infant.

Conclusion

Enoxaparin is efficient and safe for infants with congenital heart disease and catheter-related arterial thrombosis, possibly representing a valid alternative to the currently recommended unfractionated heparin.

Monagle P (2003) Thrombosis in pediatric cardiac patients. Semin Thromb Hemost 29:547–555PubMedCrossRef

Albisetti M, Schmugge M, Haas R, Eckhardt BP, Bauersfeld U, Baenziger O, Hug MI (2005) Arterial thromboembolic complications in critically ill children. J Crit Care 20:296–300PubMedCrossRef

Price V, Massicotte MP (2003) Arterial thromboembolism in the pediatric population. Semin Thromb Hemost 29:557–565PubMedCrossRef

Monagle P, Chan A, Massicotte P, Chalmers E, Michelson AD (2004) Antithrombotic therapy in children. Chest 126:645S–687SPubMedCrossRef

Hirsh J, Crowter MA (2000) Arterial thromboembolism. In: Hoffman R, Benz EJ, Shattil SI, Furie B, Cohen HJ, Silberstein LE, McGlave P (eds) Hematology: basic principle and practice, 3rd edn. Churchill Livingstone, Philadelphia, pp 2089–2096

Andrew M, Vegh P, Johnston M, Bowker J, Ofosu F, Mitchell L (1992) Maturation of the hemostatic system during childhood. Blood 80:1998–2005PubMed

Albisetti M (2003) The fibrinolytic system in children. Semin Thromb Hemost 29:339–347PubMedCrossRef

Albisetti M (2006) Thrombolytic therapy in children. Thromb Res 118:95–105PubMedCrossRef

Weitz JI (1997) Low-molecular-weight heparins. N Engl J Med 337:688–698PubMedCrossRef

10.

Albisetti M, Andrew M (2002) Low molecular weight heparin in children. Eur J Pediatr 161:71–77PubMedCrossRef

11.

Bontadelli J, Moeller A, Schmugge M, Kretschmar O, Bauersfeld U, Schraner T, Bernet-Buettiker V, Albisetti M (2006) Use of enoxaparin in the treatment of catheter-related arterial thrombosis in infants with congenital heart disease [Abstract]. Cardiol Young (Suppl) 16(2):27

12.

Monagle P, Michelson AD, Bovill E, Andrew M (2001) Antithrombotic therapy in children. Chest 119:344–370SCrossRef

13.

Streif W, Goebel G, Chan AKC, Massicotte MP (2003) Use of low molecular mass heparin (enoxaparin) in newborn infants: a prospective cohort study of 62 patients. Arch Dis Child Fetal Neonatal Ed 88:F365–F370PubMedCrossRef

14.

Michaels LA, Gurian M, Hegyi T, Drachtman RA (2004) Low molecular weight heparin in the treatment of venous and arterial thromboses in the premature infant. Pediatrics 114:703–707PubMedCrossRef

15.

Baumgartner HR (1973) The role of blood flow in platelet adhesion, fibrin deposition and formation of mural thrombi. Microvasc Res 5:167–179PubMedCrossRef

16.

Hirsh J, Levine MN (1992) Low molecular weight heparin. Blood 79:1–17PubMed

17.

Mirshahi M, Soria J, Neuhart E, Steg PG, Jacob P, Combe S, Soria C (1992) Effect of heparin and enoxaparin on platelet interaction with fibrin clots. Thromb Res 65:187–191PubMedCrossRef

18.

Serra A, Esteve J, Reverter JC, Lozano M, Escolar G, Ordinas A (1997) Differential effect of a low-molecular-weight heparin (dalteparin) and unfractionated heparin on platelet interaction with the subendothelium under flow conditions. Thromb Res 87:405–410PubMedCrossRef

19.

Jang IK, Gold HK, Ziskind AA, Fallon JT, Holt RE, Leinbach RC, May JW, Collen D (1989) Differential sensitivity of erythrocyte-rich and platelet-rich arterial thrombi to lysis with recombinant tissue-type plasminogen activator. A possible explanation for resistance to coronary thrombolysis. Circulation 79:920–928PubMed

20.

Massicotte P, Adams M, Marzinotto V, Brooker LA, Andrew M (1996) Low-molecular-weight heparin in pediatric patients with thrombotic disease: a dose finding study. J Pediatr 128:313–318PubMedCrossRef

21.

Punzalan RC, Hillery CA, Montgomery RR, Scott JP, Gill JC (2000) Low-molecular-weight heparin in thrombotic disease in children and adolescents. J Pediatr Hematol Oncol 22:137–142PubMedCrossRef

22.

Dix D, Andrew M, Marzinotto V, Charpentier K, Bridge S, Monagle P, de Veber G, Leaker M, Chan AKC, Massicotte P (2000) The use of low molecular weight heparin in pediatric patients: a prospective cohort study. J Pediatr 136:439–445PubMedCrossRef

23.

Ho SH, Wu JK, Hamilton DP, Dix DB, Wadsworth LD (2004) An assessment of published dosage guidelines for enoxaparin. J Pediatr Hematol Oncol 26:561–566PubMedCrossRef

Titel: Enoxaparin therapy for arterial thrombosis in infants with congenital heart disease
verfasst von: Joe Bontadelli
Alexander Moeller
Markus Schmugge
Thomas Schraner
Oliver Kretschmar
Urs Bauersfeld
Vera Bernet-Buettiker
Manuela Albisetti
Publikationsdatum: 01.11.2007
Verlag: Springer-Verlag
Erschienen in: Intensive Care Medicine / Ausgabe 11/2007
Print ISSN: 0342-4642
Elektronische ISSN: 1432-1238
DOI: https://doi.org/10.1007/s00134-007-0718-8

Neu im Fachgebiet AINS

24.04.2024 | DGIM 2024 | Kongressbericht | Nachrichten

Update AINS

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

hier abonnieren

Springer Medizin

Enoxaparin therapy for arterial thrombosis in infants with congenital heart disease

Abstract

Objective

Design

Setting

Patients

Measurements

Results

Conclusion

Neu im Fachgebiet AINS

Magen-Darm-Blutungen werden präklinisch oft falsch eingeschätzt

Sepsis-Verdacht: Eine Stunde, fünf essenzielle Maßnahmen

Hinter dieser Appendizitis steckte ein Erreger

Ärztliche Empathie hilft gegen Rückenschmerzen

Update AINS

Springer Medizin

Abstract

Objective

Design

Setting

Patients

Measurements

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 11/2007

Accumulation of oral antibiotics as an adverse effect of selective decontamination of the digestive tract: a series of three cases

Can we apply the European surveillance program of nosocomial infections (HELICS) to pediatric intensive care units?

The first demonstration of lactic acid in human blood in shock by Johann Joseph Scherer (1814–1869) in January 1843

The views of patients and relatives of what makes a good intensivist: a European survey

The headache over warfarin in British neurosurgical intensive care units: a national survey of current practice

RIFLE classification can predict short-term prognosis in critically ill cirrhotic patients

Neu im Fachgebiet AINS

Magen-Darm-Blutungen werden präklinisch oft falsch eingeschätzt

Sepsis-Verdacht: Eine Stunde, fünf essenzielle Maßnahmen

Hinter dieser Appendizitis steckte ein Erreger

Ärztliche Empathie hilft gegen Rückenschmerzen

Update AINS